Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
99.62 100.97 95.94 81.07 90.96 102.24 120.49 165.42 81.70 229.48
Receivables
53.65 32.01 47.84 40.35 32.53 25.54 28.90 20.77 9.67 —
Inventory
5.52 8.72 7.08 4.53 7.11 3.45 3.17 2.63 2.03 —
Other current assets
0.26 0.09 0.91 2.43 0.45 3.64 0.32 1.79 13.00 7.00
Total current assets
162.69 147.66 156.19 134.28 140.02 146.14 166.30 203.00 106.39 236.47
Property, Plant, Equpment (Net)
0.19 0.52 0.86 1.15 1.76 2.48 3.30 3.96 4.47 5.15
Goodwill and Intangible Assets (Total)
41.39 51.13 60.87 70.61 66.13 74.14 40.46 44.41 48.36 —
Long Term Assets (Tax, Deferred)
3.83 7.08 — — — — — — — —
Long-term assets (Other)
2.83 2.38 4.83 4.66 4.67 5.06 6.32 7.75 6.31 11.16
Total non-current assets
53.62 65.68 74.34 87.78 86.56 98.08 68.61 56.12 59.13 16.32
Total Assets
216.30 213.33 230.53 222.06 226.59 244.22 234.91 259.12 165.53 252.79
Accounts Payable
5.06 5.51 6.89 6.44 11.17 12.08 19.18 20.68 27.69 20.04
Accrued Expenses
50.03 36.90 52.72 65.53 92.58 82.32 69.03 46.43 30.65 17.43
Current Part of Debt
22.52 45.33 34.00 4.14 3.57 14.29 2.62 — — —
Other current liabilities
2.33 2.84 0.98 1.37 2.26 2.48 69.03 46.43 30.65 17.43
Total current liabilities
81.25 96.11 99.38 77.48 109.59 114.26 90.84 67.12 58.34 37.46
Long Term Debt (Total)
— 21.72 65.66 98.31 97.09 84.03 94.96 151.89 48.48 —
Non-current Revenue (Deferred)
— — — — — — — 5.82 5.41 5.51
Non-current Liabilities (Other)
— 1.88 5.01 12.83 6.38 32.34 9.00 5.82 5.41 5.51
Total non-current liabilities
4.71 25.10 77.70 122.97 119.45 135.92 126.61 157.70 53.88 5.51
Total liabilities
85.96 121.21 177.09 200.45 229.03 250.17 217.44 224.82 112.22 42.97
Additional Paid In Capital
1,414.07 1,407.00 1,398.61 1,388.36 1,364.31 1,331.68 1,295.03 1,236.36 1,142.21 1,006.34
Common Stock (Net)
0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Retained Earnings
(1,283.77) (1,314.89) (1,345.16) (1,366.75) (1,366.76) (1,337.63) (1,277.64) (1,202.04) (1,088.47) (796.51)
Shareholders Equity (Other)
— — — — — — — — (0.45) —
Common Equity (Total)
130.34 92.13 53.44 21.61 (2.45) (5.95) 17.46 34.31 53.30 209.82
Shareholders Equity (Total)
130.34 92.13 53.44 21.61 (2.45) (5.95) 17.46 34.31 53.30 209.82
Shareholders Equity and Liabilities (Total)
216.30 213.33 230.53 222.06 226.59 244.22 234.91 259.12 165.53 252.79
Shares (Common)
50.41 49.11 49.11 46.35 41.18 40.09 39.20 38.33 37.60 36.83
Shareholders Equity (Tangible)
88.95 40.99 (7.43) (49.00) (68.57) (80.09) (23.00) (10.10) 4.95 209.82
Net Debt
(77.10) (33.92) 3.72 21.37 9.71 (3.93) (22.91) (13.53) (33.22) (229.48)
Total Debt
22.52 67.05 99.66 102.45 100.67 98.31 97.59 151.89 48.48 —

Fold the line items

In millions of $ except per-share values · columns are period end dates